Access
To read this story in full you will need to login or make a payment (see right).
Commentary
Nature 450, 1157-1159 (20 December 2007) | doi:10.1038/4501157a; Published online 19 December 2007
Open Innovation Challenges
-
Protect Enzyme from In Planta Degradation
A proposal for stable expression of an enzyme in corn seed is desired.
-
Efficient Chromosome Doubling: Plant Cell Division
The Seeker is looking for an efficient chromosome doubling method in plants and in particular, metho...
- More Challenges
- Powered by:
nature jobs
Molecular & Human Genetics
- Indian Institute of Chemical Biology
- Kolkata India
Associate Professor / Professor ? NCRIS TERN Director
- University Of Queensland, Australia
- Brisbane, Queensland, Australia
Professor's little helper
Barbara Sahakian1 & Sharon Morein-Zamir1
- Barbara Sahakian and Sharon Morein-Zamir are at the University of Cambridge, Department of Psychiatry and the MRC/Wellcome Trust Behavioural and Clinical Neuroscience Institute, Cambridge CB2 2QQ, UK.
Abstract
The use of cognitive-enhancing drugs by both ill and healthy individuals raises ethical questions that should not be ignored, argue Barbara Sahakian and Sharon Morein-Zamir.
Today there are several drugs on the market that improve memory, concentration, planning and reduce impulsive behaviour and risky decision-making, and many more are being developed. Doctors already prescribe these drugs to treat cognitive disabilities and improve quality of life for patients with neuropsychiatric disorders and brain injury.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
